PD-L1 expression is present in approximately one-third of metastatic cancers, and the level of PD-L1 expression varies widely according to the type of primary tumor, the organ with distant metastasis, and other influencing factors, such as the treatment of chemotherapy or targeted therapy [18, 19]. The gene discussed is CD274; the disease is metastatic malignant neoplasm.